This resolution, introduced on January 14, 2026, emphasizes the critical need for the United States to strengthen its medical supply chains by fostering relationships with trusted trading partners. It highlights the growing dependency on China for essential medicines and ingredients, which poses risks to public health and national security. The resolution points out that countries like Australia, the European Union, Japan, Switzerland, and the United Kingdom are reliable suppliers that provide reciprocal tariff-free treatment for U.S. medicines. It advocates for expanding trade with these nations to mitigate supply chain disruptions and enhance access to a wider range of medical treatments.

Furthermore, the resolution calls on the President to implement policies aimed at reducing reliance on China for essential medicines and to maintain tariff-free trade with trusted partners. It urges the negotiation of bilateral or sector-specific trade agreements with these countries and advises against imposing tariffs on imports of medicines and ingredients from them. The resolution also acknowledges the complexity of medicine supply chains and the need for careful management of any changes to avoid disruptions. A copy of the resolution is to be forwarded to key government officials, including the Secretary of Commerce and the United States Trade Representative.